Bioidentical Progesterone helps sleep, hair & lower risks cancer
Lots of people have the wrong idea, that ER/PR positive means that both estrogen and progesterone are cancer causing molecules. If that were true then puberty would cause us ALL rampant breast/uterine and ovarian c. Not true at all. I had exposure to ARTIFICIAL progestins in the birth control I used, like so very many of us.
Here is another good article. They have stigmatized Progesterone unfarely, when in reality it was the ARTIFICIAL Progestins that were altered for PROFIT, that are the cancer causing molecules. Researchers were often sloppy, siting Progesterone, when they were actually talking about ARTIFICIAL progestins.
Progesterone has so many positive roles in our health, I have looked up some links to supporting research.
- Maintains the Uterine lining, reducing risks of Endometrial cancer. https://www.tandfonline.com/doi/full/10.1080/13697137.2018.1472567
- Has a benign effect on Breast Cells, inhibiting Breast Cell Overgrowth https://www.ncbi.nlm.nih.gov/pubmed/22432812
- Decreases Hot Flashes and Night Sweats https://www.endocrine.org/news-room/2018/oral-micronized-progesterone-may-decrease-perimenopausal-hot-flashes-night-sweats
- Increasing metabolism and promoting weight losshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245250/
- Balancing blood sugar levels
- Acting as a natural diuretic
- Normalizing blood clotting
- Stimulating the production of new bone https://www.ncbi.nlm.nih.gov/pubmed/22432813
- Promoting normal Sleep patterns https://academic.oup.com/jcem/article/96/4/E614/2720877
- Enhancing the action of thyroid hormones
- Alleviating depression and reducing anxiety https://www.ncbi.nlm.nih.gov/pubmed/29322164
- Improving Libido
- Preventing cyclical migraine
- restoring proper cell oxygen levels
- Decreasing Female Pattern Hair Loss https://ndnr.com/womens-health/treating-female-pattern-hair-loss/
Study Suggests Progestin, Not Estrogen, Is the Real Cancer Culprit in Hormone Replacement Therapy
Written by Ann Pietrangelo on April 26, 2015
Hormone therapy that includes progestin plus estrogen may increase breast cancer risk, but estrogen alone may lower risk, according to long-term review.
A long-term review of two clinical trials has shed new light on menopausal hormone therapy and breast cancer risk over time.
In earlier clinical trials, combination hormone replacement therapy (HRT) consisting of progestin plus estrogen was linked to an increased risk of breast cancer and death from that disease.
Women who had a hysterectomy and took estrogen alone were found to have a reduced risk of breast cancer and breast cancer death.
Following those reports, use of both types of HRT declined.
Thirteen years later, researchers set out to determine both the short-term and long-term effects of HRT.
One analysis involved 16,608 women who had not had a hysterectomy. The women were assigned to receive estrogen plus progestin. Results showed this group was at increased risk of breast cancer while taking combination HRT. Within 2.75 years after stopping therapy, the risk was still present but not as high.
Another group of 10,739 women who previously had a hysterectomy were asked to take estrogen alone. This group had a reduced risk of breast cancer while receiving estrogen therapy. That lower risk continued for a few years after therapy ended. The benefit was lost after that.
The study authors concluded there is a "greater adverse influence for estrogen and progestin use and somewhat greater benefit for use of estrogen alone."
The research team was led by Rowan T. Chlebowski, M.D., Ph.D., of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. Details were published in JAMA Oncology.
This research focused on breast cancer risk and did not involve other potential risks of HRT.